open access

Ahead of print
Review Article
Published online: 2020-12-31
Get Citation

The progress of pulmonary artery denervation

Yonghui Xie, Na Liu, Zhenghui Xiao, Fang Yang, Yunhong Zeng, Zhou Yang, Yuanxi Xia, Zhi Chen, Yunbin Xiao
DOI: 10.5603/CJ.a2020.0186
·
Pubmed: 33438182

open access

Ahead of print
Review articles
Published online: 2020-12-31

Abstract

Pulmonary arterial hypertension (PAH) is a chronic pulmonary vascular disease characterized by increased pulmonary arterial pressure and pulmonary arterioles remodeling. Some studies have discovered the relationship between sympathetic nerves (SNs) and pathogenesis of PAH. This review is aimed to illustrate the location and components of SNs in the pulmonary artery, along with different methods and effects of pulmonary artery denervation (PADN). Studies have shown that the SNs distributed mainly around the main pulmonary artery (MPA) and pulmonary artery (PA) bifurcation. And the SNs could be destroyed by three ways: the chemical way, the surgical way and the catheter-based way. PADN can significantly decrease pulmonary arterial pressure rapidly, improve hemodynamic varieties, and then palliate PAH. PADN has been recognized as a prospective and effective therapy for PAH patients, especially for those with medication-refractory PAH. However, further enlarged clinical studies are needed to confirm accurate distribution of SNs in the pulmonary artery and the efficacy of PADN.

Abstract

Pulmonary arterial hypertension (PAH) is a chronic pulmonary vascular disease characterized by increased pulmonary arterial pressure and pulmonary arterioles remodeling. Some studies have discovered the relationship between sympathetic nerves (SNs) and pathogenesis of PAH. This review is aimed to illustrate the location and components of SNs in the pulmonary artery, along with different methods and effects of pulmonary artery denervation (PADN). Studies have shown that the SNs distributed mainly around the main pulmonary artery (MPA) and pulmonary artery (PA) bifurcation. And the SNs could be destroyed by three ways: the chemical way, the surgical way and the catheter-based way. PADN can significantly decrease pulmonary arterial pressure rapidly, improve hemodynamic varieties, and then palliate PAH. PADN has been recognized as a prospective and effective therapy for PAH patients, especially for those with medication-refractory PAH. However, further enlarged clinical studies are needed to confirm accurate distribution of SNs in the pulmonary artery and the efficacy of PADN.

Get Citation

Keywords

pulmonary arterial hypertension, pulmonary artery denervation, sympathetic nerves

About this article
Title

The progress of pulmonary artery denervation

Journal

Cardiology Journal

Issue

Ahead of print

Article type

Review Article

Published online

2020-12-31

DOI

10.5603/CJ.a2020.0186

Pubmed

33438182

Keywords

pulmonary arterial hypertension
pulmonary artery denervation
sympathetic nerves

Authors

Yonghui Xie
Na Liu
Zhenghui Xiao
Fang Yang
Yunhong Zeng
Zhou Yang
Yuanxi Xia
Zhi Chen
Yunbin Xiao

References (45)
  1. Galiè N, Humbert M, Vachiery J-L, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2016; 37: 67–119.
  2. Barberà JA, Román A, Gómez-Sánchez MÁ, et al. Guidelines on the diagnosis and treatment of pulmonary hypertension: summary of recommendations. Arch Bronconeumol. 2018; 54(4): 205–215.
  3. Leopold JA. Catheter-based therapies for patients with medication-refractory pulmonary arterial hypertension. Circ Cardiovasc Interv. 2015; 8(11): e003332.
  4. Hoeper MM, Pittrow D, Opitz C, et al. and Huscher D. Risk assessment in pulmonary arterial hypertension. Eur Respir J. 2018; 51.
  5. Le T, Makar C, Morway P, et al. Pulmonary artery denervation: a novel treatment modality for pulmonary hypertension. J Thorac Dis. 2019; 11(4): 1094–1096.
  6. Kim CW, Aronow WS, Dutta T, et al. Pulmonary artery denervation as an innovative treatment for pulmonary hypertension with and without heart failure. Cardiol Rev. 2020 [Epub ahead of print].
  7. Vaillancourt M, Chia P, Sarji S, et al. Autonomic nervous system involvement in pulmonary arterial hypertension. Respir Res. 2017; 18(1): 201.
  8. Maron BA, Leopold JA. Emerging concepts in the molecular basis of pulmonary arterial hypertension: part II: neurohormonal signaling contributes to the pulmonary vascular and right ventricular pathophenotype of pulmonary arterial hypertension. Circulation. 2015; 131(23): 2079–2091.
  9. Huang Y, Liu YW, Pan HZ, et al. Transthoracic Pulmonary Artery Denervation for Pulmonary Arterial Hypertension. Arterioscler Thromb Vasc Biol. 2019; 39(4): 704–718.
  10. Thenappan T, Ormiston ML, Ryan JJ, et al. Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ. 2018; 360: j5492.
  11. de Juan A, Ince LM, Pick R, et al. Artery-Associated sympathetic innervation drives rhythmic vascular inflammation of arteries and veins. Circulation. 2019; 140(13): 1100–1114.
  12. Velez-Roa S, Ciarka A, Najem B, et al. Increased sympathetic nerve activity in pulmonary artery hypertension. Circulation. 2004; 110(10): 1308–1312.
  13. Rothman A, Jonas M, Castel D, et al. Pulmonary artery denervation using catheter-based ultrasonic energy. EuroIntervention. 2019; 15(8): 722–730.
  14. Zhang Y, Chen W, Xu Y, et al. Nerve distribution of canine pulmonary arteries and potential clinical implications. Am J Transl Res. 2016; 8: 365–374.
  15. Zhou L, Zhang J, Jiang XM, et al. Pulmonary artery denervation attenuates pulmonary arterial remodeling in dogs with pulmonary arterial hypertension induced by dehydrogenized monocrotaline. JACC Cardiovasc Interv. 2015; 8(15): 2013–2023.
  16. Rothman AMK, Arnold ND, Chang W, et al. Pulmonary artery denervation reduces pulmonary artery pressure and induces histological changes in an acute porcine model of pulmonary hypertension. Circ Cardiovasc Interv. 2015; 8(11): e002569.
  17. Watanabe S, Ishikawa K, Plataki M, et al. Safety and long-term efficacy of AAV1.SERCA2a using nebulizer delivery in a pig model of pulmonary hypertension. Pulm Circ. 2018; 8(4): 2045894018799738.
  18. Zhou X, Wang D, Castro CY, et al. A pulmonary hypertension model induced by continuous pulmonary air embolization. J Surg Res. 2011; 170(1): e11–e16.
  19. Wang W, Liu R, Cao G, et al. A reliable rabbit model for hyperkinetic pulmonary hypertension. J Thorac Cardiovasc Surg. 2010; 140(2): 395–399.
  20. Jungebluth P, Ostertag H, Macchiarini P. An experimental animal model of postobstructive pulmonary hypertension. J Surg Res. 2008; 147(1): 75–78.
  21. Juratsch CE, Jengo JA, Castagna J, et al. Experimental pulmonary hypertension produced by surgical and chemical denervation of the pulmonary vasculature. Chest. 1980; 77(4): 525–530.
  22. Jiang YH, Jiang P, Yang JL, et al. Cardiac dysregulation and myocardial injury in a 6-hydroxydopamine-induced rat model of sympathetic denervation. PLoS One. 2015; 10(7): e0133971.
  23. Kostrzewa RM, Jacobowitz DM. Pharmacological actions of 6-hydroxydopamine. Pharmacol Rev. 1974; 26(3): 199–288.
  24. Kraitchman DL, Bulte JWM. Magnetic nanoparticles and neurotoxins for treating atrial fibrillation: a new way to get burned? Circulation. 2010; 122(25): 2642–2644.
  25. Yu L, Scherlag BJ, Dormer K, et al. Autonomic denervation with magnetic nanoparticles. Circulation. 2010; 122(25): 2653–2659.
  26. Yu L, Scherlag BS, Dormer K, et al. Targeted ganglionated plexi denervation using magnetic nanoparticles carrying calcium chloride payload. JACC Clin Electrophysiol. 2018; 4(10): 1347–1358.
  27. Chrastina A, Valadon P, Massey KA, et al. Lung vascular targeting using antibody to aminopeptidase P: CT-SPECT imaging, biodistribution and pharmacokinetic analysis. J Vasc Res. 2010; 47(6): 531–543.
  28. Ogo T. Transthoracic pulmonary artery denervation. Arterioscler Thromb Vasc Biol. 2019; 39(6): 979–981.
  29. Zhang H, Chen SL. Pulmonary artery denervation: update on clinical studies. Curr Cardiol Rep. 2019; 21(10): 124.
  30. Chen SL, Zhang FF, Xu J, et al. Pulmonary artery denervation to treat pulmonary arterial hypertension. J Am Coll Cardiol. 2013; 62(12): 1092–1100.
  31. Chen SL, Zhang H, Xie DJ, et al. Hemodynamic, functional, and clinical responses to pulmonary artery denervation in patients with pulmonary arterial hypertension of different causes: phase II results from the Pulmonary Artery Denervation-1 study. Circ Cardiovasc Interv. 2015; 8(11): e002837.
  32. Zhang H, Zhang J, Chen M, et al. Pulmonary artery denervation significantly increases 6-min walk distance for patients with combined pre- and post-capillary pulmonary hypertension associated with left heart failure: the PADN-5 study. JACC Cardiovasc Interv. 2019; 12(3): 274–284.
  33. Zhang H, Zhang J, Xie DJ, et al. Pulmonary artery denervation for treatment of a patient with pulmonary hypertension secondary to left heart disease. Pulm Circ. 2016; 6(2): 240–243.
  34. Rothman AMK, Vachiery JL, Howard LS, et al. Intravascular Ultrasound Pulmonary Artery Denervation to Treat Pulmonary Arterial Hypertension (TROPHY1): Multicenter, Early Feasibility Study. JACC Cardiovasc Interv. 2020; 13(8): 989–999.
  35. Garcia-Lunar I, Pereda D, Santiago E, et al. Effect of pulmonary artery denervation in postcapillary pulmonary hypertension: results of a randomized controlled translational study. Basic Res Cardiol. 2019; 114(2): 5.
  36. Mahfoud F, Renkin J, Sievert H, et al. Alcohol-Mediated renal denervation using the peregrine system infusion catheter for treatment of hypertension. JACC Cardiovasc Interv. 2020; 13(4): 471–484.
  37. Liu C, Jiang XM, Zhang J, et al. Pulmonary artery denervation improves pulmonary arterial hypertension induced right ventricular dysfunction by modulating the local renin-angiotensin-aldosterone system. BMC Cardiovasc Disord. 2016; 16(1): 192.
  38. Chen SL, Zhang YJ, Zhou L, et al. Percutaneous pulmonary artery denervation completely abolishes experimental pulmonary arterial hypertension in vivo. EuroIntervention. 2013; 9(2): 269–276.
  39. Zhang H, Yu W, Zhang J, et al. Pulmonary artery denervation improves hemodynamics and cardiac function in pulmonary hypertension secondary to heart failure. Pulm Circ. 2019; 9(2): 2045894018816297.
  40. Tzafriri AR, Keating JH, Markham PM, et al. Arterial microanatomy determines the success of energy-based renal denervation in controlling hypertension. Sci Transl Med. 2015; 7(285): 285ra65.
  41. Fujisawa T, Kataoka M, Kawakami T, et al. Pulmonary Artery Denervation by Determining Targeted Ablation Sites for Treatment of Pulmonary Arterial Hypertension. Circ Cardiovasc Interv. 2017; 10(10): e006244.
  42. Dimopoulos K, Ernst S, McCabe C, et al. Pulmonary artery denervation: a new, long-awaited interventional treatment for combined pre- and post-capillary pulmonary hypertension? JACC Cardiovasc Interv. 2019; 12(3): 285–288.
  43. Bhatt DL, Majithia A. Continued evolution of renal artery denervation for hypertension. JACC Cardiovasc Interv. 2020; 13(4): 485–487.
  44. Kjeldsen SE, Narkiewicz K, Burnier M, et al. Renal denervation achieved by endovascular delivery of ultrasound in RADIANCE-HTN SOLO or by radiofrequency energy in SPYRAL HTN-OFF and SPYRAL-ON lowers blood pressure. Blood Press. 2018; 27(4): 185–187.
  45. Cai X, Yang Y, Shen Y, et al. Noninvasive stereotactic radiotherapy for renal denervation in a swine model. J Am Coll Cardiol. 2019; 74(13): 1697–1709.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl